

Press release

08.11.2021

WE MEASURE IMMUNITY!

The Swiss GENIUS Pharmaceutical AG offers pharmacies and physicians 10-minute immunoassays for issuing COVID-19 recovery certificates and supports the implementation of the new federal COVID-19 regulation of 3.11.2021.

- CE-certified immunoassay by Genius Pharma provides results for issuing COVID-19 certificate for convalescents
- Rapid test at the point of care in only 10 minutes for quantitative and qualitative determination of neutralising antibodies with the GENmonitor TMQT
- Swiss quality product
- The product is available immediately in Europe for healthcare professionals.

With the amendments to the Covid 19 Ordinance for Certificates of 3 November 2021, the Federal Council has created the basis that, from the cut-off date of 16 November 2021, service providers (in accordance with Annex 6 section 1.3.2), such as pharmacies and doctors, may issue certificates to convalescents for 90 days if, among other things, the current immune status is proven on the basis of antibody tests and the in-house laboratory has the corresponding authorisation.

The Swiss company Genius Pharma is able to detect neutralising antibodies against the SARS CoV-2 Spike1 protein in the blood with its GENmonitorTM, a Swiss quality product.

From today's point of view, it is not yet possible to determine 100% how long the vaccination will provide immune protection and how long the recovery will protect against contracting the Covid-19 pathogen again. This uncertainty can be TMeliminated by the CE-certified immunoassay **for recovered and vaccinated persons, the GENmonitor.**

For some time now, healthcare professionals, convalescents and vaccinated people have wanted rapid and reliable detection at the POCT (Point of Care Testing).

- **IMMEDIATELY determinable at the POC in only 10 minutes**

The quantitative determination of neutralising antibodies with the GENmonitor rapid test TM and the Smart Analyser meter is a proven method to check this in only 10 minutes.

GENmonitorTM COVID-19 NEUTRALISING Ab RAPID TEST QT, in conjunction with the Smart Analyser meter, is an excellent IVD product for the quantitative detection of neutralising IgG antibodies to the SARS CoV-2 Spike1 protein. Used by healthcare professionals, this CE-marked diagnostic assay detects neutralising antibodies in human plasma, serum or whole blood samples in as little as 10 minutes, providing information about a test subject's immunity.

Similarly, the GENmonitorTM rapid test in conjunction with the Smart Analyser meter can also record or "monitor" test results over time.

- **Test procedures can be digitally recorded and checked**

This "monitoring" is carried out after sample collection in each case already 10 minutes after testing and shows whether and how much neutralising antibodies are present and thus whether immunity against certain variants of SARS-Cov-2 can be assumed according to the current status.

GENIUS Pharma is thus taking the next logical step in the development of pandemic control. With the GENmonitorTM rapid test in combination with the Smart Analyser measuring device, medical professionals, but also the recovered and vaccinated, are thus equally able to jointly determine therapeutic measures.

For more information on the GENmonitorTM, please visit <http://www.geniuspharma.ch>.

About GENIUS Pharma

GENIUS Pharmaceutical AG distributes high quality pharmaceutical in vitro diagnostics (IVD) for applications that are commercially viable for GENIUS Pharmaceutical AG's customers while providing value to the investors behind GENIUS Pharmaceutical AG, all within a supportive and rewarding work environment for GENIUS Pharmaceutical AG employees. The goal of GENIUS Pharmaceutical AG is to improve healthcare through unconventional thinking. With its daily work, GENIUS Pharmaceutical AG wants to make a contribution to humanity. For this reason, GENIUS Pharmaceutical AG has been striving for 13 years to provide first-class healthcare solutions in a world plagued by inefficiencies and widespread discontent. This goal drives the management and employees of GENIUS Pharmaceutical AG to perform for in vitro diagnostics every day.

GENIUS Pharmaceutical AG explores innovative ways to use data and systems, leveraging the skills and expertise of the entire team to improve the management of clinical service delivery and ultimately the achievement of measurable and better health outcomes. GENIUS Pharmaceutical AG is committed to implementing health transformation by fully focusing on efficient management, cost and quality of clinical service delivery.

End of press release

This press release is intended for distribution in Germany, Austria and Switzerland only.

Schaffhausen 08.11.2021

Contact and responsible:

GENIUS Pharmaceutical AG
Feldstrasse
22CH
- 8200 Schaffhausen

Tel.: +41525880480
Fax
: +41525880481

Mail: info@geniuspharma.ch